Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Unilife Corporation
UNS
http://www.unilife.com.au
Health Care Supplies
119
264

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.45 $0.45 $0.45 $0.44 $0.46 276504 $0.01 ( 1.10% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Company Overview

Business Description
Unilife Corporation Limited (UNS) is a designer, manufacturer and supplier of innovative injectable drug delivery systems that can enhance and differentiate the injectable drugs, biologics and vaccines, or collectively injectable therapies, of pharmaceutical and biotechnology customers. UNS has a portfolio of proprietary product platforms including pre-filled syringes, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and other novel injectable drug delivery systems.
Strategy Analysis
UNS is focussed on the development, production and sale of safety syringes, the expansion of their global operational and commercial presence and, the establishment of long term supply relationships with multinational pharmaceutical and healthcare equipment companies. Unilife Corporation reported a net loss of US$27.14m for the half-year ended 31 December 2012. Revenues from ordinary activities were US$1.4m, down 54.3% from the same period last year. Basic and Diluted EPS were (0.35) US cents compared to (0.35) US cents last year. The net operating cash outflow was US$20.74m compared to an outflow of US$18.76m in the pcp. No dividend was declared.

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014 A -61.5 -62.7 0.0% 0.0 0.0 0.0% 0.0%
2013 A -68.1 -14.0 0.0% 0.0 0.0 0.0% 0.0%
2012 A -51.3 -12.7 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Ansell (ANN) $3,798M 0.1120 0.3432 0.1354 21.4014 15.9332 14.0335 1.67% 2.25% 2.56%
Nanosonics (NAN) $487M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Unilife (UNS) $120M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 7.17 0.00
Market 0.91 16.10 1.33 1.27
Sector 0.64 24.10 2.88 1.03

Directors

Name Position Start Date
Mr Alan Denis Shortall Chief Executive Officer 02/07/2009
Mr Slavko (Jim) James Joseph Bosnjak Non-Executive Chairman 05/11/2009
Mr Jeffrey Noel Carter Non-Executive Director 05/11/2009
Mr William Galle Non-Executive Director 05/11/2009
Mr John M Lund Non-Executive Director 05/11/2009
Ms Mary Katherine (Kate) Wold Non-Executive Director 11/05/2010

Management

Name Position
John Ryan Company Secretary,Senior Vice President and General Counsel
Dennis P. Pyers Interim Chief Financial Officer

Substantial Shareholders

Holding Name
0 (0%) No substantial shareholder's information disclosed

Calendar of Events

Date Event
09 February 2016 Report (Interim)
15 September 2015 Report (Annual)
28 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.